LEM Surgical, a Swiss surgical robotics company based in Bern, has successfully raised €23.6 million in a Series B funding round. The oversubscribed round attracted new investors from the United States and Switzerland, demonstrating their confidence in LEM Surgical’s innovative approach.
The funding will be used to drive the development of LEM Surgical’s robotic system and prepare for submission to the US Food and Drug Administration (FDA) in the latter half of 2024. This significant financial boost positions LEM Surgical well to achieve its goals and solidify its position in the field of surgical robotics.
Yossi Bar, the founder and CEO of LEM Surgical, expressed gratitude for the trust and support of the new investors, emphasizing their unwavering confidence in the future success of the company’s groundbreaking technology.
LEM Surgical is at the forefront of the industry, focusing on creating the next generation of robotic surgery platforms. The company’s primary objective is to surpass the capabilities of existing robotic platforms for spine surgery.
The company was founded in 2021 by a team of experts, including Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern), and Yossi Bar (previously Director R&D at Mazor Robotics Ltd).
LEM Surgical’s latest funding round not only provides a financial boost but also highlights the growing interest and investment in the advancement of surgical robotics. By combining technology with expertise in the medical field, LEM Surgical aims to revolutionize the experience for surgeons, clinical teams, and hospitals involved in robotic surgery.
With the development of its robotic system and the upcoming FDA submission, LEM Surgical is shaping the future of surgical robotics. Through their innovative approach and strong investor support, they are poised to make a significant impact and transform the field of surgery.
Overall, LEM Surgical’s successful Series B funding round marks a major milestone for the company and paves the way for further advancements in surgical robotics. With their determined focus and robust financial backing, LEM Surgical is set to redefine the landscape of robotic surgery, offering new possibilities for improved patient care and surgical outcomes.
